Amundi Sells 54,048 Shares of CureVac (NASDAQ:CVAC)

Amundi reduced its position in shares of CureVac (NASDAQ:CVAC) by 44.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 68,309 shares of the company’s stock after selling 54,048 shares during the quarter. Amundi’s holdings in CureVac were worth $233,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC bought a new stake in CureVac during the 3rd quarter valued at $35,000. Barclays PLC bought a new stake in CureVac during the 3rd quarter valued at $67,000. Public Employees Retirement System of Ohio bought a new stake in CureVac during the 3rd quarter valued at $91,000. China Universal Asset Management Co. Ltd. raised its holdings in CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after buying an additional 4,425 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after buying an additional 55,867 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors.

CureVac Stock Down 2.7 %

Shares of NASDAQ CVAC opened at $2.89 on Friday. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. CureVac has a 12 month low of $2.22 and a 12 month high of $5.28. The firm has a market capitalization of $647.01 million, a PE ratio of 5.25 and a beta of 2.53. The firm has a fifty day simple moving average of $3.49 and a two-hundred day simple moving average of $3.19.

Analyst Ratings Changes

Separately, JMP Securities restated a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a report on Friday, February 14th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.